🇺🇸 영어 원문
Researchers at the Indiana University School of Medicine have identified a potential new way to treat Alzheimer’s disease by targeting an enzyme in the brain called IDOL. In laboratory studies, removing the enzyme from neurons significantly reduced amyloid plaques, one of the main biological hallmarks of Alzheimer’s, and may also help the brain better resist damage linked to the disease.
The discovery comes as scientists continue searching for improved treatments for Alzheimer’s. In recent years, the U.S. Food and Drug Administration approved two disease modifying drugs, lecanemab and donanemab, which work by clearing amyloid plaque buildup in the brain. These treatments can help stabilize patients by slowing further decline.
The Indiana University team believes targeting IDOL could offer a different strategy for fighting Alzheimer’s while also improving communication between brain cells and supporting healthy lipid metabolism.
"What makes this exciting is that we now have a specific target that could lead to a new type of treatment," said Kim, the P. Michael Conneally Professor of Medical and Molecular Genetics. "We believe that IDOL will provide us with an alternative strategy to treat Alzheimer’s disease. Targeting enzymes in drug development offers key advantages due to their well-defined active sites or ‘pockets’ where drugs can attach and block their activity. This precision means we can design molecules that hit the right target with minimal side effects."
The findings were published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Researchers created two separate animal models of Alzheimer’s disease by deleting the IDOL gene in different brain cell types, including neurons and microglia, which are immune cells in the brain.
Scientists originally expected microglia to play the larger role in clearing amyloid plaques because these immune cells help remove harmful material from the brain and are the primary producers of IDOL.
Hande Karahan, PhD, assistant research professor of medical and molecular genetics, said deleting IDOL in neurons not only lowered plaque levels but also reduced levels of apolipoprotein E (APOE), a protein strongly associated with Alzheimer’s disease. One form of the protein, APOE4, is considered the greatest genetic risk factor for late onset Alzheimer’s disease. APOE is also important for regulating lipid metabolism in the brain.
Researchers also found increased levels of receptors involved in regulating APOE and amyloid plaques after the enzyme was removed from neurons. These receptors are important for maintaining healthy communication between neurons and supporting lipid metabolism.
Karahan said earlier research has shown that activating a related pathway may help people with Alzheimer’s remain more resistant to cognitive decline, even when significant plaque accumulation is present.
"This is especially important from a clinical perspective because patients are usually diagnosed with the disease after accumulating substantial amyloid plaque load in the brain. Not only decreasing amyloid levels but also increasing resilience to these pathological changes could maximize clinical benefits," Karahan said. "Targeting neuronal IDOL may offer multiple therapeutic benefits in Alzheimer’s disease by simultaneously reducing amyloid burden while enhancing neuroprotective effects."
The research team is now exploring several approaches for developing new treatments based on this discovery.
🇰🇷 한국어 요약
안녕하세요! 청소년 여러분, 오늘은 알츠하이머병을 치료할 수 있는 새로운 가능성을 발견한 과학자들의 연구 소식입니다. 인디애나대학교 의학전문대학원 연구팀은 뇌에 있는 ‘IDOL’이라는 효소를 표적으로 삼으면 알츠하이머병을 치료할 수 있다는 것을 밝혀냈어요. 실험실 연구에서 뉴런(신경세포) 에서 이 효소를 제거하자 알츠하이머병의 주요 특징 중 하나인 ‘아밀로이드 플라크’가 크게 줄어들었습니다. 아밀로이드 플라크는 뇌에 쌓여 뇌세포에 손상을 주는 물질인데, 이를 줄이면 뇌가 질병에 대한 저항력을 키울 수 있어요.
기존에는 뇌의 면역세포인 미세아교세포가 이 역할을 할 것이라고 생각했지만, 놀랍게도 뉴런에서 IDOL 을 제거하는 것이 더 큰 효과를 보였습니다. 이는 뇌세포 간의 소통을 원활하게 하고, 뇌의 지질 대사를 건강하게 유지하는 데 도움을 주기 때문입니다. 연구팀은 이 발견이 알츠하이머병 치료에 있어 새로운 전략이 될 수 있다고 믿고 있습니다. 약물이 정확히 표적에 작용하도록 설계할 수 있기 때문에 부작용을 줄이면서 효과를 높일 수 있는 장점이 있죠. 이 연구 결과는 알츠하이머 및 치매 관련 저널에 발표되었으며, 앞으로 더 많은 치료법 개발을 위해 연구가 계속될 예정입니다.
🔑 핵심 단어 (Vocabulary)
- Enzyme – 효소 – Removing the enzyme from neurons significantly reduced amyloid plaques.
- Neurons – 뉴런 (신경세포) – Targeting enzymes in drug development offers key advantages.
- Amyloid plaques – 아밀로이드 플라크 – These treatments can help stabilize patients by slowing further decline.
- Metabolism – 대사 – APOE is also important for regulating lipid metabolism in the brain.
- Genetic – 유전의 – APOE4 is considered the greatest genetic risk factor for late onset Alzheimer’s disease.
- Receptors – 수용체 – Researchers also found increased levels of receptors involved in regulating APOE.
- Cognitive – 인지적인 – Activating a related pathway may help people with Alzheimer’s remain more resistant to cognitive decline.
- Therapeutic – 치료적인 – Targeting neuronal IDOL may offer multiple therapeutic benefits in Alzheimer’s disease.
- Resilience – 회복탄력성/저항력 – Increasing resilience to these pathological changes could maximize clinical benefits.
- Pathological – 병리적인 – Not only decreasing amyloid levels but also increasing resilience to these pathological changes.
🔗 원문 링크
https://www.sciencedaily.com/releases/2026/05/260519224334.htm